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Abstract
Great attention was recently given to the importance of RAS in controlling
inflammatory bone diseases, following the discovery of its local existence in
skeletal tissues. Local RAS was found to be expressed on osteoblastic and
osteoclastic cells and to exert its action via angiotensin II (AngII) receptors,
including angiotensin II type 1 receptor (AT1R) and angiotensin II type
2 receptors. Telmisartan (TLM), an AT1R blocker (ARBs), was investigated
in the present study for its therapeutic effect on bone health in osteoporotic
rats. D-Galactose, a reducing sugar at a dose of 200 mg/kg/day/i.p., was
used to induce osteoporosis in male rats. TLM, at a dose of 5 mg/kg/day,
was orally introduced in the osteoporotic rats for four consecutive weeks.
Tibia and femur bone densitometry was estimated, bone formation and
bone resorption biomarkers serum levels were measured, mineral content
in blood was also valued, and finally the extracellular regulated kinase
(ERK) expression in bone was determined. TLM considerably improved the
deleterious effect of D-galactose on bone mineral density. It blunted serum
bone-specific alkaline phosphatase and osteocalcin while elevating serum
osteoprotegrin (OPG). On the other hand, TLM turned off the pronounced
elevation in serum receptor activator of nuclear factor-κβ ligand (RANKL),
tartrate-resistant acid phosphatase, and cathepsin K. Furthermore,
it significantly hindered the bone expression of ERK which hampered
osteoclastogenesis. AT1R inhibition abolished the rise in serum calcium and
phosphorus and normalized serum superoxide dismutase and catalase.
These TLM protective effects in D-galactose-treated rats were confirmed by
the histopathological examination. The results all together denote the
potential therapeutic value of ARBs therapy in osteoporosis.
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angiotensin receptor blockerosteoporosis, D-galactose, extracellular regulated kinase, rats
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1 | INTRODUCTION
Linkage between aging, renin-angiotensin system
(RAS), and osteoporosis has been recently explored.
RAS is an eminent endocrine system that rules body
fluids, electrolyte balance, and therefore blood pressure
[1]. Hypertensive patients can simply develop osteoporosis due to the local existence of RAS in bone cells [2].
The octapeptide angiotensin II (AngII) generated from
the inactive dectapeptide angiotensin I (AngI) by the
cleavage action of angiotensin converting enzymes
(ACE) was found to regulate bone metabolism and
remodeling through angiotensin II type 1 receptor
(AT1R) and type 2 receptor (AT2R) that were found to
be located on the osteoblasts (OBs) and osteoclasts
(OCs) [3, 4].
Aging-induced osteoporosis involved mitochondrial
dysfunction, production of reactive oxygen species
(ROS), and subsequently activation of Ang II [5].
Pathological effects of RAS are exerted through the
classical ACE/AngII/AT1 pathway that promotes
different intracellular signaling resulting in endothelial
dysfunction, hypertension, and inflammation, which
makes it an important target for antihypertensive
drugs such as ACE inhibitors and angiotensin II
receptor blocker (ARB) [6]. OBs were found to be
repressed by effect of AngII through inhibition of
osteocalcin (OCN) and diminishing of bone-specific
alkaline phosphatase (BALP) via AT1R as mentioned
in previous studies [7, 8]. On the contrary, it has been
reported that AngII accelerates the incidence of osteoporosis by differentiating OCs through overexpression of receptor activator of nuclear factor-κβ
ligand (RANKL) above the osteoprotegrin (OPG) on
OBs [9]. AngII also causes an upsurge in tartrateresistant acid phosphatase (TRAP) and cathepsin K
(CTSK) that are essential to osteoclastogenesis [10].
Moreover, it can lead to activation of extracellular regulated kinases which subsequently triggers OCs [11].
Notably, AngII dramatically impairs the vascular
superoxide dismutase (SOD) and catalase (CAT)
activity [12].
Telmisartan (TLM) is an angiotensin type II receptor
blocker (ARB) used as antihypertensive agent. It selectively blocks AT1R and therefore inhibits the binding of
angiotensin to its receptor in vasculature as well as in
bone [13]. It catalyzes the conversion of AngII to Ang
1–7 via overexpressing the angiotensin converting
enzyme-2 (ACE-2) and thus hampers the AngII/AT1
axis and subsequently prevents the pathological effect
of RAS. The effect of Ang 1–7 is mediated via G-protein
coupled receptor entitled Mas receptor [14]. Moreover,
TLM may also mediate its antioxidant and antiinflammatory effect through triggering the peroxisome
proliferator activated receptor gamma [15]. Noteworthy,
long-term use of ARBs showed lower fracture incidence
in men more than the ACE inhibitors and the calcium
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channel blockers in a prospective cohort study in elder
hypertensive osteoporotic.
The present study was designed to characterize the
effect of the activation of renin–angiotensin system in
bone and its consequences on bone resorption using
D-galactose and to examine the therapeutic value of
TLM as AT1R blocker on osteoporosis induced in male
albino rats. To achieve this goal, osteoporosis is
induced in rats by intraperitoneal injection of D-gal
(200 mg/kg/day) for 8 weeks. TLM (5 mg/kg/day) is
used in counteracting the osteoporotic rats. At the end
of the investigation, femoral and tibia densitometry is
determined via dual energy X-ray absorptiometry
(DEXA). Serum calcium and phosphorus are also performed to evaluate the bone density. Moreover, bone
turnover biomarkers as well as redox homeostasis status and bone ERK are also determined. In addition, histopathological examination is carried out to confirm the
aforementioned outcomes.

2 | MATERIAL AND METHODS
2.1 | Experimental animal
In the current study, 36 male Wistar albino rats
weighing 150 to 180 g were provided from the animal
house colony of the National Research Center
weighing. They were retained under proper environmental conditions during the period of investigation:
proper temperature (25  2 C), humidity (60  10%),
and alternating 12 h light–dark cycles. They had free
access to standard rat pellet diet and water. The
experimental protocol of this study was in agreement
with the National Institute of Health Guidelines (NIH
Publications No. 80-23; 1996). In addition, ethical
approval was provided for the present study by the
research Ethical Committee, Faculty of Pharmacy,
Cairo University, Cairo, Egypt (ethical approval
No. PT-208).

2.2 | Study design
The experimental animals were divided into three
groups of 10 rats after 2 weeks of habituation period.
Group I: normal control rats received equivalent volume
of saline serving as a control group, Group II: rats
received D-galactose at a dose of 200 mg/kg/day,
i.p. (1 ml each) for 8 weeks and served as osteoporotic
rats, Group III: rats received D-galactose at a dose
200 mg/kg/day, i.p. for eight consecutive weeks and
concurrently treated with TLM at a dose 5 mg/kg/day
for four successive weeks starting in the fifth week after
D-galactose administration. The dose of D-galactose
was established on a former study [16]. Doses of TLM
were designated based on the earlier study [17]. Blood
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samples were collected and kept frozen at 70 C.
Tibia and femur bone samples were then removed, and
soft tissues were washed off to be scanned for bone
densitometry.

2.3 | Determination of femoral and tibia
bone densitometry using central dual
energy X-ray absorptiometry (DEXA)
To examine bone density, soft tissues were removed
off the femur and tibia bone after rats had been
sacrificed and then located beneath the scanner arm of
a Norland XR-46 to perform a DEXA scan. Bone mineral content (BMC) in grams and area in cm2 are two
important parameters required to accomplish the scan
by sending a thin visible beam of low dose X-ray
through the bone. After scanning, the information is
stored by the computer unit and used to calculate bone
mineral density (BMD) in g/cm2 by dividing BMC over
area of bone measured.

2.4 | Determination of calcium and
phosphorus levels in blood
Serum calcium (Ca+2) and phosphorus (P) were
determined colorimetrically using commercial kits (Biodiagnostic, Cairo, Egypt). Absorbance were measured
at 585 nm according to the method described by
Gindler and King [18] and at 640 nm according to the
method described by El-Merzabani et al. [19], respectively. Serum concentrations in mg/dl were then
calculated.

2.5 | Determination of bone turnover
biomarkers
The serum concentration of bone-specific alkaline
phosphatase
(BALP),
osteocalcin
(OC),
and
osteoprotegrin (OPG), tartrate-resistant acid phosphatase (TRAP), receptor activator of nuclear factor kappa
beta ligand (RANKL), and cathepsin K (CTSK) were
estimated using the respective sandwich ELISA kit
(Biotang Inc., Waltham, Massachusetts, USA).

2.6 | Measurement of anti-oxidant
enzymes
The oxidoreductases catalase (CAT) in U/L and superoxide dismutase (SOD) in U/ml serum activity were
estimated using colorimetric kit (Bio-diagnostic, Cairo,
Egypt) at 510 nm according to the method described by
Aebi [20] and at 560 nm according to the method
described by Rao et al. [21].

3

2.7 | Quantitative Western blot of bone
proteins
ReadyPrep™ protein extraction kit supplied by Bio-Rad
Inc. (Catalog #163-2086) was used on equipped testers
of the scraped bone tissues in accordance with the
manufacturer constructions. Likewise, Bradford Protein
Assay Kit (Cat # SK3041, Bio Basic Inc., Ontario,
Canada) was utilized for quantitative measurements of
protein assay. Additionally, parting of the protein samples based on the difference in their molecular weight
was carried out on a polyacrylamide gel in a regular
running buffer following encumbering of 20 μg of total
protein into each mini-gel well. Later, the gel was congregated in a transferal sandwich with PVDV membrane, located in an allocation container (Bio-Rad
Trans-Blot Turbo) with 1 transfer buffer, to allow protein bands movement from gel to membrane. Trisbuffered saline containing Tween 20 (TBST) and 3%
bovine serum albumin (BSA) was used at lukewarm to
dilute the Primary ERK, AT1, and AT2 antibody concentrations according to the constructor’s instructions,
allowing for full membrane blockage for 1 h. In the primary antibody solution, together with the designated
targeted protein, an overnight incubation at 4 C was
performed. HRP-conjugated secondary antibody solution (goat anti-rabbit IgG- HRP-1 mg goat mAb -Novus
Biologicals) was supplemented to the membrane.
Aforementioned incubation took place against the blotted target protein for 1 h at ambient temperature. The
chemiluminescent substrate (ClarityTM Western ECL
substrate Bio-Rad cat#170-5060) was applicable to the
blot conferring to the constructor’s endorsement. Furthermore, a computer program was used to evaluate
the images through interpretation of the band intensity
of the marked proteins opposing the control tester beta
actin; housekeeping protein on the ChemiDoc MP
imager. The primary antibody against ERK (Cat # sc1647) was purchased from Santa Cruz Biotechnology,
Inc. (Dallas, Texas, USA), whereas the primary antibody against AT1 receptor (Cat # MBS2535008) and
AT2 receptor (Cat # ADI-905-746-100) were bought
from Biocompare and Enzo, respectively. Additionally,
the secondary antibody (goat anti-rabbit IgG; HRP1 mg goat mAb) was acquired from Novus Biologicals
(Littleton, Colorado, USA).

2.8 | Histopathological examination
The detached bone was preserved in 10% neutral buffered formalin for 48 h and then were fixed in 10% ethylene
diamine
tetra-acetic
acid
(EDTA)
for
decalcification. Tissue handling was done through
graded ethanol, xylol, and paraffin for dehydration,
clearing, impregnation, and embedding. Histologic sections with a thickness of 6 μm were arranged and
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afterword they were regularly tainted with hematoxylin
and eosin.

3.2 | Effect of TLM on bone
minerals and bone formation
biomarkers in D-galactose-induced
osteoporotic rats

2.9 | Statistical analysis
The results are presented as mean  SEM and were
statistically analyzed using one-way ANOVA followed
by Tukey’s multiple comparisons test. GraphPad Prism
software version 5 (La Jolla, CA, USA) was employed
for the statistical analysis. Statistical significance was
established at *P < 0.05 versus normal control group
and @P < 0.05 versus D-galactose-treated group.

3 | RESULTS
3.1 | Effect of TLM on bone mineral
density in D-galactose-induced
osteoporotic rats

Treatment with D-galactose for eight consecutive weeks
boosted serum calcium and lessened serum phosphorus by 89% and 32%, respectively, above the normal
values. It also up-surged serum BALP and OCN by
about 3- and 1-fold of the control values. D-Galactose
hindered serum OPG by 36% from the control value.
These results were regarded to the control group. On
the other hand, TLM turned off the aforementioned
parameters and augmented serum phosphorus and
OPG back to normal in the order of the control group as
illustrated in Table 2.

3.3 | Effect of TLM on anti-oxidant
enzymes in D-galactose-induced
osteoporotic rats

Results in Table 1 showed that D-galactose-treated rats
exhibited a dramatic decrease in BMD of both femur
and tibia by 53% and 74%, respectively, after eight consecutive weeks as compared with the control group.
However, treatment with TLM for four successive
weeks opposed the D-galactose effect on tibia and
femur and restored them back to normal.

The osteoporotic model demonstrated a prominent
decrease in serum SOD and serum CAT by about
35% and 36% respectively regarding the control
group as depicted in Table 3. Treatment with TLM
has restored the antioxidant enzymes to their normal
levels.

T A B L E 1 Effect of TLM on bone mineral density in D-galactoseinduced osteoporotic rats

T A B L E 3 Effect of TLM on antioxidants biomarkers in Dgalactose-induced osteoporotic rats

Parameters

Parameters
2

Groups

Femur (g/cm )

2

Tibia (g/cm )

Groups

Serum SOD (U/ml)

Serum CAT (U/L)

Control

0.134  0.001

0.118  0.001

Control

0.0116  0.0001

0.59  0.007

D-Gal

0.085*  0.001

0.065*  0.002

D-Gal

0.0075*  0.0004

0.38*  0.023

0.130@  0.003

0.113@  0.003

D-Gal

0.0110@  0.0002

0.60@  0.009

D-Gal

+ TLM

Note: Tibia bone and femur bone were scanned using a regional highresolution scan of the right and left femurs. Results are expressed as
mean  SEM (n = 8–10). Data were statistically evaluated using one-way
ANOVA followed by Tukey’s multiple comparisons test.
*Differences were considered statistically significant when P < 0.05 compared
with the control group. @Differences were considered statistically significant
when P < 0.05 compared with D-gal-treated group.

TABLE 2

+ TLM

Note: Serum superoxide dismutase and serum catalase were determined using
UV–visible spectrophotometer. Results are expressed as mean  SEM
(n = 8–10). Data were statistically evaluated using one-way ANOVA followed
by Tukey’s multiple comparisons test.
*Differences were considered statistically significant when P < 0.05 compared
with the control group. @Differences were considered statistically significant
when P < 0.05 compared with D-gal-treated group.

Effect of TLM on bone minerals and bone formation biomarkers in D-galactose-induced osteoporotic rats
Parameters

Groups
Control
D-Gal
D-Gal

+ TLM

Serum calcium
(mg/dl)

Serum phosphorus
(mg/dl)

8.56  0.35

5.03  0.07

16.26*  0.36

3.40*  0.05

8.48@  0.15

5.16@  0.09

Serum BALP
(ng/ml)

Serum OCN
(ng/ml)

2.84  0.07

5.48  0.29

11.5*  0.60

11.0*  0.57

3.98@  0.12

6.09@  0.59

Serum OPG
(pg/ml)
961.5  10.6
618.4*  29.7
978.1@  8.26

Note: Serum calcium and serum phosphorus were determined using UV–visible spectrophotometer. Serum BALP, serum OCN, and serum OPG were determined
using the sandwich ELISA technique. Results are expressed as mean  SEM (n = 8–10). Data were statistically evaluated using one-way ANOVA followed by
Tukey’s multiple comparisons test.
*Differences were considered statistically significant when P < 0.05 compared with the control group. @Differences were considered statistically significant when
P < 0.05 compared with D-gal-treated group.
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3.4 | Effect of TLM on bone resorption
biomarkers in D-galactose-induced
osteoporotic rats
Treatment with D-galactose triggered and bolstered
serum RANKL (a) by 1.5-fold which in-turn evoked
serum CTSK (b) and TRAP (c) by 2.2- and 3-folds,
respectively, as compared with the control group. Following 4 weeks’ treatment with TLM palliated and
abolished the immense rise in the above-mentioned
parameters as presented in Figure 1.

3.5 | Effect of TLM on bone ERK
protein kinase and AT1 and AT2
receptors in D-galactose-induced
osteoporotic rats
ERK protein, AT1, and AT2 receptors were measured in
bone using western blot method to determine their
effect on the osteoclastogenesis in bone matrix as
demonstrated in Figure 2. Osteoporotic group has
shown a dramatic elevation in ERK protein and AT1
receptor by about 1.2- and 1.6-folds, respectively, while
AT2 receptors was blunted by 48% as compared with
the control group. Once more, treatment with TLM significantly mitigated ERK protein and AT1 receptor by
51% and 60%, respectively, whereas AT2 receptor was
elevated back to normal.

F I G U R E 1 Effect of TLM on
bone resorption biomarkers in Dgalactose-induced osteoporotic
rats. Serum (a) RANKL, serum
(b) CTSK, and serum (c) TRAP
were determined using the
sandwich ELISA technique.
Results are expressed as
mean  SEM (n = 8–10). Data
were statistically evaluated using
one-way ANOVA followed by
Tukey’s multiple comparisons
test. Differences were
considered statistically
significant when *P < 0.05
compared with the control group
and @P < 0.05 compared with Dgal-treated group

5

3.6 | Effect of TLM on histopathology in
D-galactose-induced osteoporotic rats
Figure 3 shows a longitudinal photomicrograph of the
cancellous bone and expresses the histological scoring
report on the osteoporotic induced bone. Bone tissues
isolated from the D-galactose treated group (c) and
(d) exhibited unevenly eroded endosteal surface and
resorption cavities. Multinucleated osteoclasts with an
acidophilic cytoplasm were also confined. In addition,
loss of normal bone trabeculae architecture with an
apparent increase in intertrabecular gap resulted in a
marked increase in entangled bone marrow spaces and
an apparent increase in adipocytes relative to the control
group (a) and (b) with normal bone structure. TLM therapy reversed bone resorption and preserved bone
microarchitecture compared to control group. This displayed no significant enlargement in the spaces of the
interconnecting bone marrow suggesting fewer adipocytes. In addition, presence of osteocytes was also
observed in trabecula bone along with enhancement of
trabecular structure. The histopathological score corresponded to [22] as illustrated in Table 4.

4 | DISCUSSION
Age-related bone loss induced by D-galactose through
the activation of RAS locally in skeletal tissues plays a

6
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F I G U R E 2 Effect of TLM on
femoral bone head expression of
AT1 (a), AT2 (b) receptors, and
ERK protein kinase (c) in Dgalactose-induced osteoporotic
rats. Determined using Western
blot technique. Results are
expressed as mean  SEM
(n = 8–10). Data were
statistically evaluated using oneway ANOVA followed by Tukey’s
multiple comparisons test.
Differences were considered
statistically significant when
*P < 0.05 compared with the
control group and @P < 0.05
compared with D-gal-treated
group

pivotal role in bone remodeling and metabolism [23, 24].
In the current study, treatment with D-galactose dramatically augmented the expression of AT1R in bone
over AT2R, which was consistent with a former study
conducted by [5] in D-galactose-induced aging in rats.
The conventional ACE/AngII/AT1 axis triggered ROS
formation and consequently oxidative stress through
stimulation of NADPH oxidase which oxidized the
intracellular NADPH into NADP+ and thus reduced the
molecular oxygen to super oxide anions [25]. The
increase in oxidative stress caused imbalance

between ROS formation and oxidoreductases that was
assured by the significant decrease in antioxidants
serum levels SOD and CAT in the present study. The
data coincide with a previous one [26] in ovariectomized rats. Notably, a deleterious relationship was
indicated by [27] between the increase in oxidative
stress and bone mineral density (BMD) that could elicit
bone loss and alter the mechanical property of bone
as witnessed in the existing study. Blocking of AT1R
with TLM improved BMD of both tibia and femur as
well as increased the serum levels of antioxidants

TELMISARTAN REGULATES OSTEOCLASTOGENESIS
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(c)

(d)

(e)

(f)

F I G U R E 3 Effect of TLM on histopathological examination in D-galactose-induced osteoporotic rats. Section of (c) and (d) D-gal-induced
osteoporosis group shows irregularly eroded endosteal surface and resorption cavities, irregular thickness of the remaining trabeculae,
osteoclasts with their acidophilic cytoplasm and multiple nuclei were observed housed in the eroded bone surface as well as an increase in bone
marrow adipocytes compared with the (a) and (b) control groups that showed normal histological structure. Section of (e) and (f) telmisartantreated group shows an improvement in the arrangement of bone trabeculae, fewer adipocytes, no resorption cavities, and interconnected bone
marrow spaces containing hemopoietic cells. The image analysis of % of osteoporosis values represents the mean  S.E.M. Data were
statistically evaluated using one-way ANOVA followed by Tukey’s multiple comparisons test. Differences were considered statistically significant
when *P < 0.05 compared with the control group and @P < 0.05 compared with D-gal-treated group

TABLE 4
with TLM

Histopathological scoring of osteoporotic rats treated
Groups
+ TLM

Parameters

Control

D-Gal

D-Gal

% of osteoporosis

0 (<5%)

2+ (50–75%)*

1 (<25%)@

Note: The histopathological sections were examined for osteoporosis in three
different fields. Data are expressed as median (min-max) and analyzed using
Kruskal–Wallis followed by Dunn’s multiple comparison test.
*Differences were considered statistically significant when P < 0.05 compared
with the control group. @Differences were considered statistically significant
when P < 0.05 compared with D-gal-treated group.

enzymes. Likewise, olmesartan an AT1R blocker ameliorated osteoporosis induced and enhanced bone
density in ovariectomized rats [9].
AngII signaling was augmented through AT1R,
which in-turn hindered the uptake of calcium by the
bone, suppressed osteoblastic bone formation cells,

and stimulated osteoclastic bone resorption cells [28].
Elevated serum calcium level and reduced serum phosphorus were observed in the current study, which might
be associated with vitamin D deficiency in blood and
thus amplified RAS suggesting enhanced osteoclastic
activity [29, 30]. Moreover, a previous study revealed
that high serum calcium levels can modulate bone remodeling by controlling the expression of RANKL on
osteoblastic cells [31]. Additionally, AngII increased
serum BALP and OCN, which are important proteins
for the synthesis of the bone matrix that subsidized for
the inhibition of calcium precipitation in bone and differentiation of OCs [32, 33]. Treatment with TLM attenuated osteoclastogenesis by inhibiting AngII action on
AT1R and thus restored bone formation markers,
enhanced calcium mineralization, and consequently
the BMD. The data coincide with a previous study in
estrogen-deficient mice [34] and also in spontaneously
ovariectomized hypertensive rats [35].
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F I G U R E 4 Diagram showing the
different mechanisms upon which TLM
prevents osteoclastogenesis.
Abbreviations: AngII, angiotensin II; AT1R,
angiotensin II type 1 receptor; AT2R,
angiotensin II type 2 receptor; CTSK,
cathepsin K; ERK, extracellular regulated
kinase; JNK, C-Jun N terminal kinase;
OCs, osteoclasts; OPG, osteoprotegrin;
RANKL, receptor activator of nuclear
factor-κβ ligand; ROS, reactive oxygen
species; TRAP, tartrate-resistant acid
phosphatase

As it has been highlighted in the current work, AngII
upregulated the AT1R, which then triggered the mitogen activated kinase series and therefore provoked the
surge of serum ERK. This comes in harmony with [36]
in Dahl salt-sensitive rats. The pronounced elevation of
ERK contributed for the upregulation of RANKL
together with a significant decline in serum OPG and
thereby altered RANKL/OPG ratio and hence activated
and differentiated OCs [31]. Collectively, these findings
indicated that ERK is an important key mediator for the
AngII induced osteoporosis. Increased serum levels of
the protease enzymes CTSK and TRAP in the present
work stipulated enhanced osteoclastic activity. They
are both released from the ruffled borders of the
multinucleated OCs to initiate degrading the main components of the bone matrix [37]. These data come in
harmony with a recent study [38] in a model of osteoarthritis in adult male rats. The osteo-protective effects of
TLM informed in the current study were associated with
downregulation in AT1R and upregulation of AT2R,
which markedly hampered serum ERK, blunted serum
RANKL, and evoked serum OPG thus restoring
RANKL/OPG ratio back to normal. Consequently, TLM
abolished the activation of inflammatory mediators as
well as inhibited OCs differentiation and hence ROS
formation [39]. However, a previous study stated that
blocking AT2R enhanced bone mass [6]. Notably, TLM
indirectly abated the increase in serum CTSK and

TRAP by normalizing OPG levels thus eradicated
the degradation of bone matrix by OCs [40].
Likewise, losartan abated CTSK activity in wild-type
embryos [41].

5 | CONCLUSION
Facts that were signified in current study verify the
anti-inflammatory capacity of TLM as well as its antiosteoporotic effect. Turning-off the action of AngII via
contributed
to
controlling
blocking
AT1R
osteoclastogenesis by eradicating the triggering of
ERK protein which subsequently normalized the
RANKL/OPG ratio and hence prevented bone degradation as demonstrated in Figure 4. It also
replenished BALP, OCN, and calcium levels which
subsidize in regulating RANKL activation. These
results assured that RAS is involved in the pathogenesis of osteoporosis and confirmed that hindering AT1
receptor by TLM is very likely to have a therapeutic
significance.
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